Optimal dose of dexmedetomidine for sedation when combined with chloral hydrate in pediatric patients with non-cyanotic congenital heart diseases undergoing computed tomography

金立红,黄佳佳,张马忠
DOI: https://doi.org/10.3760/cma.j.cn131073.20200423.01217
2020-01-01
Abstract:Objective:To determine the optimal dose of dexmedetomidine for sedation when combined with chloral hydrate in pediatric patients with non-cyanotic congenital heart diseases (CHD) undergoing computed tomography (CT).Methods:A total of 211 children of both sexes with CHD undergoing CT scan under sedation with chloral hydrate and dexmedetomidine, aged 6 months to 3 yr, were divided into 3 groups using a random number table method: D1 group ( n=69), D2 group ( n=71) and D3 group ( n=71). Chloral hydrate 50 mg/kg was administrated orally, and dexmedetomidine 1.0, 1.5 and 2.0 μg/kg was administrated intranasally in D1, D2 and D3 groups, respectively.The onset time of drugs, success of sedation at first attempt, time to emergence, and adverse reactions were recorded. Results:There were no significant differences in the incidence of onset time of drugs, success rate of sedation at first attempt, emergence time, bradycardia, respiratory depression, and the lowest heart rate after sedation and the lowest pulse oxygen saturation among the three groups ( P>0.05). Conclusion:For sedation in pediatric patients with non-cyanotic CHD undergoing CT, oral chloral hydrate 50 mg/kg combined with intranasal dexmedetomidine 1.0 μg/kg is recommended, and it has a reliable sedative effect and little effect on respiratory and circulatory function with a higher safety.
What problem does this paper attempt to address?